Multicenter Retrospective Analysis of Second-Line Therapy after Gemcitabine Plus Nab-Paclitaxel in Advanced Pancreatic Cancer Patients

Multicenter Retrospective Analysis of Second-Line Therapy after Gemcitabine Plus Nab-Paclitaxel in Advanced Pancreatic Cancer Patients

Pancreatic cancer is one of the most lethal solid tumors. In many European countries gemcitabine plus nab-paclitaxel is the preferred first-line treatment. An increasing number of patients are eligible for second-line therapy, but the best regimen is still controversial. This study aimed to evaluate...

Full description

Bibliographic Details
Main Authors: Valeria Merz, Alessandro Cavaliere, Carlo Messina, Massimiliano Salati, Camilla Zecchetto, Simona Casalino, Michele Milella, Orazio Caffo, Davide Melisi
Format: Article
Language:English
Published: MDPI AG 2020-04-01
Series:Cancers
Subjects:
pancreatic cancer
second-line therapy
nal-IRI
nab-paclitaxel
Online Access:https://www.mdpi.com/2072-6694/12/5/1131

Internet

https://www.mdpi.com/2072-6694/12/5/1131

Similar Items